Head-To-Head Contrast: Calidi Biotherapeutics (NYSE:CLDI) & iTeos Therapeutics (NASDAQ:ITOS)

iTeos Therapeutics (NASDAQ:ITOS) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Profitability

This table compares iTeos Therapeutics and Calidi Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iTeos Therapeutics	N/A	-20.11%	-17.50%
Calidi Biotherapeutics	N/A	N/A	-344.45%

Valuation and Earnings

This table compares iTeos Therapeutics and Calidi Biotherapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iTeos Therapeutics	$12.60 million	21.14	-$112.64 million	($3.15)	-2.31
Calidi Biotherapeutics	$50,000.00	319.10	-$29.22 million	N/A	N/A

Calidi Biotherapeutics has lower revenue, but higher earnings than iTeos Therapeutics.

Risk & Volatility

iTeos Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.

Insider & Institutional Ownership

97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for iTeos Therapeutics and Calidi Biotherapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iTeos Therapeutics	0	0	4	0	3.00
Calidi Biotherapeutics	0	0	3	0	3.00

iTeos Therapeutics currently has a consensus price target of $22.25, indicating a potential upside of 205.21%. Calidi Biotherapeutics has a consensus price target of $16.67, indicating a potential upside of 1,266.12%. Given Calidi Biotherapeutics’ higher possible upside, analysts clearly believe Calidi Biotherapeutics is more favorable than iTeos Therapeutics.

About iTeos Therapeutics

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.